Knight Therapeutics Inc (TSE:GUD) has been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is C$10.15.
Several equities research analysts recently weighed in on the company. Bloom Burton restated an “accumulate” rating on shares of Knight Therapeutics in a report on Friday. TD Securities increased their target price on Knight Therapeutics from C$9.50 to C$10.00 in a report on Friday, August 10th.
Shares of GUD stock opened at C$8.30 on Friday. Knight Therapeutics has a 1-year low of C$7.38 and a 1-year high of C$8.81.
Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, November 8th. The company reported C$0.03 earnings per share for the quarter, meeting the consensus estimate of C$0.03. The company had revenue of C$3.22 million for the quarter, compared to analysts’ expectations of C$2.26 million. As a group, equities research analysts anticipate that Knight Therapeutics will post 0.130000001435583 earnings per share for the current fiscal year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Recommended Story: How dollar cost averaging works
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.